UroToday

ASTRO 2025: Validation of a Prognostic Multimodal Artificial Intelligence Model in Asian Prostate Cancer Patients from Singapore

(UroToday.com) The 2025 ASTRO annual meeting featured a predictive markers in prostate cancer session and a presentation by Dr. Melvin L. K. Chua discussing validation of a prognostic multimodal ...
UroToday

ASTRO 2025: Testosterone Recovery post ADT in Intermediate Risk Prostate Cancer Patients: Does a Higher Dose of Radiotherapy Impact on Survival? Long-Term Data from a Phase III ...

In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery to normal level is associated with a significant improvement in overall ...
UroToday

ASTRO 2025: Interim Analysis of a Phase 2 Single Arm Trial of Extended Lymph Node Proton Irradiation for High Risk Prostate Cancer

(UroToday.com) The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco between September 28 and September 30 was host to the Session QP 13 - GU 7: Quick Pitch: ...
UroToday

ASTRO 2025: Discordance of Adverse Molecular Features between the 22-Gene Genomic Classifier Score, Histologic Grade, and NCCN Risk Groups: Analysis of Over 200,000 Patients

The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade tumors. There was an observed nearly 20-fold increase in the presence of ...
UroToday

ASTRO 2025: A Phase I/Ib, Single Arm Study of Two Fraction SBRT with Simultaneous Integrated Boost for the Treatment of Localized Prostate Cancer: Early Toxicity Outcomes

Primary physician reporting grade 2+ toxicity per CTCAE version 5.0 was the primary endpoint. Follow-up was performed 30 days post-treatment and subsequently every 3 to 4 months for 2 years: ...